ArticleFrontiers in pharmacology2018
Protective Effect of Salidroside Against Diabetic Kidney Disease Through Inhibiting BIM-Mediated Apoptosis of Proximal Renal Tubular Cells in Rats.
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Anti-inflammatory and antioxidant effects of salidroside in diabetic nephropathy: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2026Pooled it
- Urinary microenvironment-degradable nanocapsules for traceable therapy of diabetic nephropathy.Materials today. Bio · 2026Article
- Yishen Tongluo formula ameliorates kidney injury modulating inflammation and apoptosis in streptozotocin-induced diabetic kidney disease mice.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Therapeutic potential ofInternational journal of medical sciences · 2025Article
- Targeting programmed cell death in diabetic kidney disease: from molecular mechanisms to pharmacotherapy.Molecular medicine (Cambridge, Mass.) · 2024Review
- Observational
- High CD133 expression in proximal tubular cells in diabetic kidney disease: good or bad?Journal of translational medicine · 2024Article
- Claudin-2 Mediates the Proximal Tubular Epithelial Cell-Fibroblast Crosstalk via Paracrine CTGF.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Cellular crosstalk of mesangial cells and tubular epithelial cells in diabetic kidney disease.Cell communication and signaling : CCS · 2023Review
- Article
- Assessment of Effects of Rosemary Essential Oil on the Kidney Pathology of Diabetic Adult Male Albino Rats.Cureus · 2023Article
- Role of renal tubular programed cell death in diabetic kidney disease.Diabetes/metabolism research and reviews · 2023Review
- Pharmacological functions of salidroside in renal diseases: facts and perspectives.Frontiers in pharmacology · 2023Review
- Protective effect of salidroside on streptozotocin-induced diabetic nephropathy by inhibiting oxidative stress and inflammation in rats via the Akt/GSK-3β signalling pathway.Pharmaceutical biology · 2022Article
- Identifying the mechanisms and molecular targets of Hongjingtian injection on treatment of TGFβ1-induced HK-2 cells: coupling network pharmacology with experimental verification.Annals of translational medicine · 2022Article
- Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases.Frontiers in pharmacology · 2022Review
- hsa-miR-199b-3p Prevents the Epithelial-Mesenchymal Transition and Dysfunction of the Renal Tubule by Regulating E-cadherin through Targeting KDM6A in Diabetic Nephropathy.Oxidative medicine and cellular longevity · 2021Article
- Variability of Major Phenyletanes and Phenylpropanoids in 16-Year-OldMolecules (Basel, Switzerland) · 2020Article
- MicroRNA-24-3p inhibition prevents cell growth of vascular smooth muscle cells by targeting Bcl-2-like protein 11.Experimental and therapeutic medicine · 2020Article
- Salidroside Alleviates Cartilage Degeneration Through NF-κB Pathway in Osteoarthritis Rats.Drug design, development and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.